Getinge’s acquisition of Healthmark Industries for approximately $320m is expected to enhance its presence in the US sterile reprocessing market.
The deal, brokered by investment bank Stout, will help Getinge improve its consumable offerings and its sterilisation and reprocessing equipment. With a 17x estimated earnings before interest, taxes, depreciation, and amortisation (EBITDA) multiple for 2023 this is being touted as an ambitious move by Getinge.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Stout managing director John Calcagnini, who led the deal team, said: “We see an enormous opportunity for Getinge to expand distribution of Healthmark products to its’ international customers, as Healthmark generates 90% of revenue in the US today.
“We don’t see why they could not grow the business to the point where international represents 50% of the mix, which is what we see with other large medical device manufacturers.”
In its fiscal year ending 31 October 2023, Healthmark’s predicted revenue is expected to increase 15% to $126m.
In other news, Getinge has had a string of US Food and Drug Administration (FDA) recalls this year with the recent Class I recall being just the latest in a long line of issues for the Cardiosave IABPs.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe first, which occurred in January, involved more than 4,400 devices due to a faulty catheter. There were two more recalls in March and an earlier one in August. The most recent recall for Getinge’s troubled IABP device was in September, bringing the total to six recalls this year.
